PDP1 and breast cancer: Using CPI-613 (150 μM), a dual inhibitor of PDH and OGDH activities (Figure 8H), at 48 h of treatment, we do not observe changes in the viability, however, the combination FRI-1 (25 μM) plus CPI-613 produced extensive death in both BC cell lines (Figure 8A,B).